Furthermore, the genomic region containing the WIP1 locus (17q23.2) has been reported to be frequently amplified in several human malignancies where TP53 mutations are less common, including breast cancers, ovarian clear cell adenocarcinomas, neuroblastomas, and pancreatic cancers [47–49]. Here, TP53 is linked to breast carcinoma.